AnGes has been granted a patent for a non-naturally occurring composition that includes a CRISPR nuclease with a sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3. This composition could have significant implications for gene editing and genetic engineering. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A patent granted for a non-naturally occurring crispr nuclease composition
A recently granted patent (Publication Number: US11666641B2) describes a non-naturally occurring composition that includes a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nuclease. The CRISPR nuclease has a sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3.
The composition can also include a CRISPR RNA (crRNA) molecule and a transactivating CRISPR RNA (tracrRNA) molecule, or a single-guide RNA (sgRNA) molecule. These molecules do not naturally occur together with the CRISPR nuclease. The guide sequence portion of the crRNA or sgRNA molecule consists of 17-24 nucleotides, and it can further include a repeat sequence portion or a tracrRNA sequence portion.
The composition may also include a donor template molecule, which can be a DNA or RNA molecule. The CRISPR nuclease can have a nuclear localization sequence (NLS) and can be linked to another protein. Additionally, the composition can include a DNA molecule encoding a crRNA molecule, a tracrRNA molecule, both a crRNA molecule and a tracrRNA molecule, or a sgRNA molecule.
The patent also describes methods of targeting or modifying a nucleotide sequence at a target site in a cell's genome using the composition. This involves introducing the nucleic acid molecule encoding the CRISPR nuclease into the cell, along with the crRNA and tracrRNA molecules or the sgRNA molecule. The method can also include introducing a donor template molecule.
Furthermore, the patent covers a method of treating a subject with a mutation disorder by introducing the composition into a cell of the subject.
Overall, this patent describes a non-naturally occurring composition and methods for using it to target and modify nucleotide sequences in a cell's genome, as well as its potential application in treating mutation disorders.
To know more about GlobalData’s detailed insights on AnGes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
